Varicose Vein Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Varicose veins affect approximately 23% of adults globally, making them the most prevalent vascular condition. They result from incompetent venous valves allowing retrograde blood flow (reflux) in the superficial venous system, causing progressive dilation and tortuosity of the great saphenous vein (GSV), small saphenous vein (SSV), or their tributaries. Chronic venous insufficiency is classified by the CEAP system: C0 (no signs), C1 (telangiectasias), C2 (varicose veins), C3 (edema), C4 (skin changes), C5 (healed ulcer), C6 (active venous ulcer). Treatment is tailored to CEAP stage, anatomy confirmed by duplex ultrasound mapping, and patient preference. Conservative management with class II compression stockings (20–30 mmHg) reduces symptoms but does not ablate the vein. Endothermal ablation is the most common definitive treatment: endovenous laser ablation (EVLA) and radiofrequency ablation (RFA, ClosureFast system) deliver thermal energy inside the GSV or SSV under ultrasound guidance after tumescent anesthesia infiltration, causing irreversible thermal damage and vein fibrosis. Non-thermal non-tumescent (NTNT) techniques include cyanoacrylate glue (VenaSeal—no tumescent anesthesia required, same-day return to activity) and mechanochemical ablation (MOCA/Clarivein). Foam or liquid sclerotherapy treats telangiectasias, reticular veins, and residual varicosities after truncal ablation. Conventional high ligation and stripping is now less preferred due to higher recurrence rates and longer recovery. Ambulatory phlebectomy removes tributary varicosities through tiny stab incisions under local anesthesia.

Symptomatic varicose veins (CEAP C2) with aching, heaviness, itching, and cramping—particularly worsening through the day and relieved by leg elevation—are treated when compression stockings fail or are not tolerated. Varicose veins complicated by superficial thrombophlebitis (painful, red, indurated cord along the vein) require treatment after the acute episode resolves to prevent recurrence. Venous edema (C3) causing ankle and lower leg swelling responds well to ablation of underlying truncal reflux combined with compression. Lipodermatosclerosis (hardened, discolored skin, C4a) and venous eczema (C4a) indicate advanced chronic venous insufficiency requiring reflux correction to halt progression. Active venous ulceration (C6) demands urgent duplex assessment and ablation of incompetent truncal veins to promote healing; the ESCHAR trial demonstrated that ablation significantly improves ulcer healing rates and reduces recurrence from 56% to 31% at 3 years. Great saphenous vein reflux (extending from saphenofemoral junction to below knee in most cases) is the most common cause, treated by EVLA or RFA targeting the GSV from knee to groin. Small saphenous vein reflux at the saphenopopliteal junction is treated by SSV ablation. Recurrent varicose veins after prior surgery or ablation may require re-ablation, stab avulsion, or ultrasound-guided foam sclerotherapy (UGFS) for neovascularization.

Duplex ultrasound mapping is mandatory before any varicose vein treatment. It confirms reflux location (SFJ, SPJ), vein diameter, course, and depth, and identifies perforating vein incompetence or DVT. EVLA and RFA are first-line for truncal GSV or SSV reflux per NICE guidelines (TA 2013), preferred over surgery and foam sclerotherapy for primary treatment. GSV diameter of 3–12 mm is optimal for endothermal ablation; very large veins (greater than 20 mm) may require multiple passes. Pregnancy is an absolute deferral; treatment is offered 6 months post-partum or after cessation of breastfeeding. Superficial thrombophlebitis at the planned ablation site requires anticoagulation and a delay of 4–6 weeks before ablation. DVT history does not contraindicate treatment if deep veins are patent on duplex. Patients with significant arterial disease (ABI below 0.8) should use compression with caution; bypass arterial disease should be assessed before applying high compression. Sclerotherapy (foam or liquid) is first-line for telangiectasias (C1) and small reticular veins, and as adjunct to ablation for residual varicosities. VenaSeal (cyanoacrylate) is ideal for patients unable to tolerate tumescent anesthesia or compression, or who need immediate return to full activity, though allergy testing is advisable.

Varicose vein treatment has evolved from open surgery toward minimally invasive thermal ablation and foam sclerotherapy as first-line options. Endovenous thermal ablation — laser (EVLA/EVLT) and radiofrequency ablation (RFA, VNUS ClosureFast, Medtronic) — is now the recommended first-line treatment per NICE (TA232) and European guidelines for great saphenous vein (GSV) incompetence. Under tumescent anaesthesia (subcutaneous perivenous injection of dilute lidocaine with adrenaline), a laser fibre or RFA catheter is introduced into the GSV via ultrasound-guided access and thermally occludes the vein from within (temperatures 100–120°C for laser; 85°C for RFA). 5-year occlusion rates of 80–90% are comparable between EVLA and RFA; RFA has lower post-procedure bruising and pain in some trials. Non-thermal, non-tumescent (NTNT) techniques include: cyanoacrylate glue (VenaSeal) — adhesive closure without anaesthesia or compression; mechanochemical ablation (MOCA, ClariVein) — rotational wire plus polidocanol injection; and adhesive endovascular system (Sapheon). These newer techniques avoid needles for tumescent anaesthesia, improving the patient experience. Ultrasound-guided foam sclerotherapy (UGFS) using 1–3% polidocanol or sodium tetradecyl sulphate (STS) foam directly targets incompetent veins, junction reflux, and recurrent veins with minimal equipment. GSV ablation success at 5 years is 70–80% — somewhat lower than thermal ablation. Traditional high ligation and stripping (H+S) under general or spinal anaesthesia is now rarely performed as a primary procedure but remains appropriate for very large varicosities, anatomical variants, and complex recurrence. Phlebectomy (ambulatory or stab avulsion) removes branch varicosities through 2–3 mm micro-incisions and is performed as a complementary procedure at the same session as thermal ablation.

Endothermal ablation techniques are the most effective definitive treatments for GSV and SSV reflux. Radiofrequency ablation (RFA/ClosureFast) achieves 88–90% vein occlusion at 5 years with significantly less post-procedure bruising and pain compared to surgical stripping. EVLA achieves 90–95% occlusion at 3 years and was compared directly to RFA and surgery in the CLASS trial: EVLA showed slightly superior procedural success rates; both were superior to conventional surgery in early recovery, bruising, and return to work. The EVOLVeS trial confirmed EVLA's superiority over stripping at 2 years for occlusion rates and patient satisfaction. VenaSeal cyanoacrylate achieves 88–92% occlusion at 3 years without the need for tumescent anesthesia, compression stockings, or time off work—patients can return to normal activity the same day. Symptom improvement (aching, heaviness, itching) is reported by 80–90% of patients after successful GSV ablation. For active venous ulcers (C6), treating underlying reflux accelerates ulcer healing and reduces 3-year recurrence from 56% to 31% (ESCHAR trial). Superficial thrombophlebitis recurrence is significantly reduced after GSV ablation. Ambulatory phlebectomy for tributary varicosities is performed simultaneously or staged 6–12 weeks after truncal ablation, removing visible vein clusters with excellent cosmetic outcomes.

EVLA complications include bruising along the treated vein course (60–70%, typically resolving within 2–4 weeks), phlebitis (tender palpable cord, 10–15%), thermal injury to adjacent saphenous nerve (inner ankle and lower leg numbness, 1–5%, most recover within 6–12 months), skin burns from excessive laser energy or inadequate tumescent infiltration (rare, less than 1%), and DVT including endothermal heat-induced thrombosis (EHIT—thrombus extending into the deep system, 1–2%; EHIT grade III/IV requires anticoagulation). RFA (ClosureFast) carries similar risks with lower bruising rates. VenaSeal carries a small risk of hypersensitivity or anaphylaxis to cyanoacrylate (less than 0.5%), skin phlebitis along the glued vein, and a slightly higher early failure rate compared to thermal techniques, particularly for very large or tortuous veins. Foam sclerotherapy complications include skin pigmentation (10–30%, usually transient over months), allergic or anaphylactic reaction to sclerosant (1–3%), headache and visual disturbances from intracardiac passage of foam via patent foramen ovale (2–3%, transient), neovascularization or matting (10–20%), and DVT with foam sclerotherapy (0.1–0.2%). Conventional surgical stripping has higher complication rates including wound hematoma, lymphocele, infection, and saphenous nerve injury compared to endothermal techniques. Long-term recurrence of varicose veins (from neovascularization at the saphenofemoral junction or disease progression) affects 20–30% at 5–10 years, potentially requiring retreatment.

Clinical and duplex ultrasound review at 4–6 weeks post-procedure confirms trunk vein occlusion and absence of complications. Duplex assessment specifically evaluates: GSV occlusion rate, EHIT (endovenous heat-induced thrombus) — thrombotic extension into the deep venous system, graded 1–4 — which requires anticoagulation for EHIT class 3–4. EHIT occurs in 0.5–3% after EVLA/RFA. Class 1–2 EHIT (thrombus projecting less than 50% into the deep vein at the saphenofemoral junction) resolves spontaneously with compression and LMWH. Varicose vein clinical classification (CEAP: C0–C6) is re-assessed at each visit: C4 (skin changes — lipodermatosclerosis, white atrophy) and C5–C6 (healed and active ulcers) require dressing, compression management, and recurrence monitoring. Class II medical compression stockings (23–32 mmHg) are prescribed for 2 weeks post-procedure. Residual branch varicosities requiring phlebectomy or repeat foam sclerotherapy are addressed at 3-month follow-up. Annual clinical review thereafter monitors for recurrence — rates of significant clinical recurrence at 5 years are 15–25% regardless of primary treatment modality, often from neovascularisation at the saphenofemoral junction.

Varicose vein treatment costs vary by technique and country. In India, duplex ultrasound mapping costs USD 50–150. EVLA or RFA for one limb costs USD 1,500–4,000 at private hospitals in Delhi, Mumbai, Bangalore, and Chennai, making India a preferred destination for medical tourists. VenaSeal costs USD 2,000–5,000 in India due to device costs. Foam sclerotherapy sessions cost USD 200–600 per session, with 2–4 sessions typically required for complete treatment. Conventional high ligation and stripping costs USD 1,000–3,000 in India. In Thailand, EVLA or RFA costs USD 2,000–5,000 at Bangkok Hospital and Bumrungrad International. Turkey offers EVLA at USD 1,500–4,000. In the United Kingdom, NICE guidelines recommend endothermal ablation as first-line; NHS treats varicose veins with documented C4–C6 complications or symptomatic C2 disease at no patient cost. Private UK treatment ranges GBP 1,500–3,500 per limb. In the United States, EVLA and RFA cost USD 3,000–8,000 per limb and are partially covered by insurance when symptoms are documented and compression therapy has failed. VenaSeal in the US costs USD 4,000–9,000 per limb. Germany charges EUR 2,000–5,000 for endothermal treatment. Patients traveling to India or Thailand for bilateral varicose vein treatment can achieve savings of USD 4,000–12,000 versus US private pricing.

Conservative management with compression stockings — class 1 (18–21 mmHg) for mild symptomatic varicosities or class 2 (23–32 mmHg) for significant venous hypertension, oedema, and skin changes — reduces symptoms and slows progression but does not eliminate varicosities. Compression is maintained indefinitely after ablation and is the only management appropriate for asymptomatic small varicosities. Sclerotherapy without ultrasound guidance (visual sclerotherapy) is appropriate for small reticular veins and telangiectasias (spider veins) using 0.25–0.5% polidocanol or 0.5% STS, achieving 60–80% clearance with 2–3 sessions. Spider vein laser therapy using 1064 nm Nd:YAG or 532 nm KTP cutaneous laser targets dermal telangiectasias where sclerotherapy is impractical (small calibre, poor accessibility). Surface laser is less effective than sclerotherapy for 1–3 mm reticular veins. Combined approaches — ablation of the incompetent saphenous trunk combined with simultaneous sclerotherapy or phlebectomy of branch varicosities — achieve the most comprehensive aesthetic and functional outcome in a single session. For symptomatic chronic venous insufficiency without significant reflux, pentoxifylline or rutosides (venotonic agents) have modest evidence for reducing oedema and improving skin changes.